drugset / Trial / NCT01535950

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950

Phase 2 Completed 43 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.

Timeline

Start
2012-02
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject tesidolumab Monoclonal antibody Intravitreal